T1 mapping of the myocardium: Intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Kawel, Nadine ^a,b   Nacif, Marcelo ^a,b   Zavodni, Anna ^a,b   Jones, Jacquin ^a   Liu, Songtao ^a,b   Sibley, Christopher T ^a,b   Bluemke, David A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

ECV; Extracellular volume fraction; Gadobenate dimeglumine; Gadopentetate dimeglumine; Modified Look Locker Inversion Recovery; T1 mapping

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; BLOOD; BOLUS INJECTION; CARDIOVASCULAR MAGNETIC RESONANCE; FEMALE; HEART MUSCLE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; COMPUTER ASSISTED DIAGNOSIS; FIBROSIS; HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PATHOLOGY; PREDICTIVE VALUE; REFERENCE VALUE; REPRODUCIBILITY; TIME; UNITED STATES;

ADULT; CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HEART DISEASES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MARYLAND; MEGLUMINE; MYOCARDIUM; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; YOUNG ADULT;

EID: 84862213151     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-26     Document Type: Article

References (35)

1. Assessment of myocardial viability by cardiovascular magnetic resonance imaging. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Eur Heart J. 2002 23 602 619 10.1053/euhj.2001.3038 11969275 (Pubitemid 35204245)
2. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ, J Am Coll Cardiol. 2008 52 1574 1580 10.1016/j.jacc.2008.06.049 19007595
3. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution-reproducibility study. Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivananthan MU, Radiology. 2006 238 1004 1012 10.1148/radiol.2382041903 16424239 (Pubitemid 43289933)
4. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M, Circ Cardiovasc Imaging. 2010 3 727 734 10.1161/CIRCIMAGING.108.842096 20855860
5. Cardiovascular magnetic resonance in cardiac amyloidosis. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ, Circulation. 2005 111 186 193 10.1161/01.CIR. 0000152819.97857.9D 15630027 (Pubitemid 40139730)
6. Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging. Been M, Thomson BJ, Smith MA, Ridgway JP, Douglas RH, Best JJ, Muir AL, Eur Heart J. 1988 9 1250 1256 3234418 (Pubitemid 19010177)
7. Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study. Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G, Sivananthan MU, AJR Am J Roentgenol. 2006 187 630 W635 10.2214/AJR.05.1264 17114517
8. T(1) mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. Gai N, Turkbey EB, Nazarian S, van der Geest RJ, Liu CY, Lima JA, Bluemke DA, Magn Reson Med. 2011 65 1407 1415 10.1002/mrm.22716 21500267
9. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Flacke SJ, Fischer SE, Lorenz CH, Radiology. 2001 218 703 710 11230643 (Pubitemid 32172551)
10. Assessment of Diffuse Myocardial Fibrosis in Rats Using Small Animal Look-Locker Inversion Recovery (SALLI) T1 Mapping. Messroghli D, Nordmeyer S, Dietrich T, Dirsch O, Kaschina E, Savvatis K, OHI D, Klein C, Berger F, Kuehne T, Circ Cardiovasc Imaging. 2011
11. Effect of Gd-DTPA-BMA on blood and myocardial T1 at 1.5T and 3T in humans. Sharma P, Socolow J, Patel S, Pettigrew RI, Oshinski JN, J Magn Reson Imaging. 2006 23 323 330 10.1002/jmri.20504 16456820 (Pubitemid 43364058)
12. Reperfused rat myocardium subjected to various durations of ischemia: estimation of the distribution volume of contrast material with echo-planar MR imaging. Arheden H, Saeed M, Higgins CB, Gao DW, Ursell PC, Bremerich J, Wyttenbach R, Dae MW, Wendland MF, Radiology. 2000 215 520 528 10796935 (Pubitemid 30237855)
13. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, Schick F, Invest Radiol. 2006 41 213 221 10.1097/01.rli.0000197668. 44926.f7 16481903 (Pubitemid 44406181)
14. Left ventricular infarct size assessed with 0.1mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2mmol/kg of gadopentetate dimeglumine. Tumkosit M, Puntawangkoon C, Morgan TM, Clark HP, Hamilton CA, Ntim WO, Clark PB, Hundley WG, J Comput Assist Tomogr. 2009 33 328 333 10.1097/RCT.0b013e318187fed0 19478622
15. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Schneider G, Maas R, Schultze Kool L, Rummeny E, Gehl HB, Lodemann KP, Kirchin MA, Invest Radiol. 2003 38 85 94 10.1097/00004424-200302000-00003 12544071 (Pubitemid 36125892)
16. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. Aime S, Caravan P, J Magn Reson Imaging. 2009 30 1259 1267 10.1002/jmri.21969 19938038
17. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Spinazzi A, Lorusso V, Pirovano G, Kirchin M, Acad Radiol. 1999 6 282 291 10.1016/S1076-6332(99)80451-6 10228617 (Pubitemid 32673373)
18. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ, Invest Radiol. 2005 40 715 724 10.1097/01.rli.0000184756.66360. d3 16230904 (Pubitemid 41546838)
19. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Balci NC, Inan N, Anik Y, Erturk MS, Ural D, Demirci A, Acad Radiol. 2006 13 833 839 10.1016/j.acra.2006.04.002 16777557 (Pubitemid 43866530)
20. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Kuwatsuru R, Kadoya M, Ohtomo K, Tanimoto A, Hirohashi S, Murakami T, Tanaka Y, Yoshikawa K, Katayama H, Invest Radiol. 2001 36 632 641 10.1097/00004424-200111000-00002 11606840 (Pubitemid 33021091)
21. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP, Magn Reson Med. 2004 52 141 146 10.1002/mrm.20110 15236377 (Pubitemid 39295266)
22. Myocardial T1 and Extracellular Volume Fraction Mapping at 3 Tesla. Lee JJ, Liu S, Nacif MS, Ugander M, Kawel N, Sibley CT, Kellman P, Arai A, Bluemke DA, J Cardiovasc Magn Reson: official journal of the Society for Cardiovasc Magn Reson. 2011 13 75
23. An open-source software tool for the generation of relaxation time maps in magnetic resonance imaging. Messroghli DR, Rudolph A, Abdel-Aty H, Wassmuth R, Kuhne T, Dietz R, Schulz-Menger J, BMC Med Imaging. 2010 10 16 10.1186/1471-2342-10-16 20673350
24. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS, Circulation. 2002 105 539 542 10.1161/hc0402.102975 11815441 (Pubitemid 34262671)
25. T1, T2 relaxation and magnetization transfer in tissue at 3T. Stanisz GJ, Odrobina EE, Pun J, Escaravage M, Graham SJ, Bronskill MJ, Henkelman RM, Magn Reson Med. 2005 54 507 512 10.1002/mrm.20605 16086319 (Pubitemid 41233744)
26. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. Piechnik SK, Ferreira VM, DallArmellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD, J Cardiovasc Magn Reson. 2010 12 69 10.1186/1532-429X-12-69 21092095
27. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Kellman P, Jones BL, Ludwig DR, Schwartzman D, et al. J Cardiovasc Magn Reson. 2011 13 16 10.1186/1532-429X-13-16 21375743
28. Albumin-bound MRI contrast agents: the dilemma of the rotational correlation time. Vander Elst L, Laurent S, Bintoma HM, Muller RN, MAGMA. 2001 12 135 140 10.1007/BF02668095 11390269 (Pubitemid 32510132)
29. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE, Am J Physiol Heart Circ Physiol. 2008 295 1234 H1242 10.1152/ajpheart.00429.2008 18660445
30. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC, Circulation. 2010 122 138 144 10.1161/CIRCULATIONAHA.109.930636 20585010
31. Feasibility of the single-bolus strategy for measuring the partition coefficient of Gd-DTPA in patients with myocardial infarction: independence of image delay time and maturity of scar. Thornhill RE, Prato FS, Wisenberg G, White JA, Nowell J, Sauer A, Magn Reson Med. 2006 55 780 789 10.1002/mrm.20830 16508912
32. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE, Eur Heart J. 2012 [Epub ahead of print].
33. Incorporation of excess gadolinium into human bone from medical contrast agents. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE, Metallomics. 2009 1 479 488 10.1039/b905145g 21305156
34. Intraarticular diffusion of Gd-DOTA after intravenous injection in the knee: MR imaging evaluation. Drape JL, Thelen P, Gay-Depassier P, Silbermann O, Benacerraf R, Radiology. 1993 188 227 234 8511303 (Pubitemid 23183129)
35. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. White GW, Gibby WA, Tweedle MF, Invest Radiol. 2006 41 272 278 10.1097/01.rli.0000186569.32408.95 16481910 (Pubitemid 44406188)